Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

62.76
-1.9800-3.06%
Post-market: 62.760.00000.00%19:51 EDT
Volume:2.24M
Turnover:140.91M
Market Cap:5.92B
PE:-131.72
High:64.89
Open:64.89
Low:62.47
Close:64.74
52wk High:68.73
52wk Low:22.06
Shares:94.26M
Float Shares:92.77M
Volume Ratio:1.44
T/O Rate:2.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:241.25
PE(LYR):-219.17

Loading ...

Travere Therapeutics SVP, Chief Accounting Officer Sandra Calvin Disposes of $335,983 in Common Shares

Reuters
·
Yesterday

Travere Therapeutics Grants Inducement RSUs Covering 56,220 Shares to 16 New Employees

Reuters
·
Sep 12

Travere Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 12

Travere Therapeutics Director Jeffrey A. Meckler Disposes of Common Shares Worth $1.31 Million

Reuters
·
Sep 12

Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations

Simply Wall St.
·
Aug 20

Travere Therapeutics Director Gary A. Lyons Disposes of USD 629,150 in Common Shares

Reuters
·
Aug 20

Travere Therapeutics Posts Corporate Overview on Rare Kidney Disease Growth Strategy, Filspari Expansion and Pipeline Updates

Reuters
·
Aug 14

Travere Therapeutics Grants 38,940 Inducement RSUs to 12 New Employees

Reuters
·
Aug 13

Travere Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)

TIPRANKS
·
Aug 12

Ardelyx Says Q2 Product Revenue at Record High but Ibsrela Revenue Below Expectations

Reuters
·
Aug 07

Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
Aug 06

Travere Therapeutics, Inc. : Wedbush Raises Target Price to $75 from $61

THOMSON REUTERS
·
Aug 06

Regulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships

TIPRANKS
·
Aug 06

Travere Therapeutics to Present at Canaccord Genuity Growth Conference

Reuters
·
Aug 06

Akebia Q2 Revenue Falls on Lower Auryxia Sales

Reuters
·
Aug 06

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Reuters
·
Aug 06

Mirum Pharmaceuticals Q2 Sales Rise, Lifts Outlook

Reuters
·
Aug 06

Does FILSPARI-Driven Revenue Growth And Wider Losses Change The Bull Case For Travere Therapeutics (TVTX)?

Simply Wall St.
·
Aug 06

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Reuters
·
Aug 05